Patents Assigned to Yeda Research and Development Co., Ltd.
  • Patent number: 11028127
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 8, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • Publication number: 20210162025
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Application
    Filed: February 3, 2021
    Publication date: June 3, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irit SAGI, Eitan WONG, Ran AFIK
  • Publication number: 20210154261
    Abstract: An article of manufacture is disclosed which comprises: (i) a peptide agent which is capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus; and (ii) a MEK inhibitor. Uses thereof are also disclosed.
    Type: Application
    Filed: July 24, 2018
    Publication date: May 27, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yardena SAMUELS, Rand ARAFEH, Karen FLORES, Rony SEGER, Ehud WAINSTEIN
  • Publication number: 20210156867
    Abstract: This invention is directed to a turn-on fluorescent probe, wherein said probe comprises a quinoline based cyanine dye derivative (QBC) and a specific protein binder covalently attached thereto directly or via a linker. This invention is further directed to His-tag binding compounds and uses thereof in the preparation of genetically targeted detectable molecules and sensors which can specifically bind tag-labeled proteins. This invention further describes methods for using these turn-on probes and compounds for detecting and labelling a wide range of proteins in their native environment.
    Type: Application
    Filed: January 3, 2021
    Publication date: May 27, 2021
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: David MARGULIES, Leila MOTIEI, Pragati PRASAD, Tom GRANOT, Ohad SUSS
  • Publication number: 20210147575
    Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.
    Type: Application
    Filed: February 7, 2021
    Publication date: May 20, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Deborah FASS, Iris GROSSMAN, Tal ILANI
  • Publication number: 20210144999
    Abstract: The present invention provides anti-microbial compositions comprising a hydroxycinnamic acid and related conjugates, analogues and derivatives, and methods of use thereof for enhancing production of anti-microbial agents in bacteria as well as for protecting plants from microbial infection.
    Type: Application
    Filed: July 9, 2018
    Publication date: May 20, 2021
    Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
    Inventors: Ilana KOLODKIN-GAL, Yaara OPPENHEIMER-SHAANAN, Ariel OGRAN-NACHMAN, Michael MEIJLER, Eliane Hadas YARDENI
  • Publication number: 20210142905
    Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.
    Type: Application
    Filed: January 18, 2021
    Publication date: May 13, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Eran SEGAL, Eran ELINAV
  • Patent number: 11002735
    Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: May 11, 2021
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. Cohen, Eytan Domany, Francisco Javier Quintana, Guy Hed, Gad Getz
  • Patent number: 10995141
    Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
    Type: Grant
    Filed: April 19, 2020
    Date of Patent: May 4, 2021
    Assignees: ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd.
    Inventors: Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
  • Publication number: 20210115092
    Abstract: A recombinant system for improving genome editing via homologous recombination is disclosed. The system comprising a first nucleic acid sequence encoding a DNA editing agent having a double strand DNA cutting activity and a second nucleic acid sequence encoding a polypeptide capable of increasing homologous recombination in a target cell.
    Type: Application
    Filed: June 25, 2019
    Publication date: April 22, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yosef SHAUL, Nina REUVEN
  • Patent number: 10981989
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: April 20, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 10975373
    Abstract: A method of treating a bipolar disorder in a subject in need thereof is disclosed. The method comprising administering to the subject sa therapeutically effective amount of a miR-135, a precursor thereof or a nucleic acid molecule encoding said miR-135 or said precursor thereof, thereby treating the bipolar disorder. Methods of diagnosing a mood disorder in a human subject and of monitoring treatment of an anti-depressant drug or a medicament for the treatment of a mood disorder are also disclosed.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 13, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Alon Chen, Orna Issler
  • Patent number: 10961309
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: March 30, 2021
    Assignee: Yeda Research and Development Co. Ltd
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 10961504
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: March 30, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
  • Patent number: 10940111
    Abstract: A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: March 9, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Jacob Klein, Ronit Goldberg, Jasmine Seror, Weifeng Lin, Reut Mashiach
  • Patent number: 10933124
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 2, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Eran Ophir, Yaki Eidelstein, Rotem Gidron Budovsky
  • Patent number: 10933134
    Abstract: A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 2, 2021
    Assignees: Memorial Sloan Kettering Cancer Center, Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science
    Inventors: Jonathan Coleman, Philip A. Watson, Kwanghee Kim, Avigdor Scherz
  • Patent number: 10938486
    Abstract: An optical bus for multi-core processing providing optical data transfer between cores through a single planar waveguide employing a variable-thickness, light-propagation layer having a progressively changing effective refractive index in accordance with lateral position within the light-propagation layer such that light emission from a single light emitter in communication with one core is focused on each of multiple photodetectors in communication with its respective processer core.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: March 2, 2021
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventor: Ulf Leonhardt
  • Patent number: 10933122
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 2, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Eitan Wong, Ran Afik
  • Publication number: 20210052626
    Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.
    Type: Application
    Filed: November 5, 2020
    Publication date: February 25, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Idit SHACHAR, Hadas LEWINSKY, Lihi RADOMIR, Anna WIENER